Option chain shows key data for Senti Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Senti Biosciences.

Senti Biosciences (NASDAQ:SNTI) Stock, Option Chain

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

woman-6318447

News

SNTI

Senti Biosciences shares are trading higher by 102.6% during Monday&#39;s session. The company was awarded $8 million from the California Institute for Regenerative Medicines.

Senti Biosciences (SNTI) Stock Is Up Over 100%: What&#39;s Happening?

Biotech

Penny Stocks

Health Care

Movers

General

Senti Biosciences Inc (NASDAQ: SNTI) received FDA clearance for its Investigational New Drug (IND) application for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hemato

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

Earnings

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

ALTO

DDOG

OPRT

TMDX

UBER

VTYX

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 1% on Tuesday

The Dow traded up 0.21% to 34,166.89 while the NASDAQ rose 1.09% to 13,666.65. The S&amp;P 500 also rose, gaining, 0.41% to 4,383.80.

Crude Oil Falls Sharply; Datadog Shares Spike Higher

Senti Biosciences Inc

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares increased by 28.2% to $5.16 during Wednesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 26.07% to $2.74. The market value of their outstanding shares is at $4.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock moved upwards by 20.59% to $0.11. The company's market cap stands at $5.8 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock increased by 19.78% to $10.9. The market value of their outstanding shares is at $385.1 million. </li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) stock increased by 14.51% to $21.0. The company's market cap stands at $252.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares increased by 12.7% to $1.27. The market value of their outstanding shares is at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares declined by 15.6% to $0.14 during Wednesday's regular session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 12.97% to $2.55. The market value of their outstanding shares is at $11.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares declined by 11.66% to $2.88. The company's market cap stands at $4.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 10.74% to $0.48. The market value of their outstanding shares is at $1.3 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares decreased by 10.65% to $19.84. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares declined by 10.64% to $0.41. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

CAPR

CERO

CRBP

ERNA

FTRE

OGEN

STSS

TNON

VTAK

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Senti Biosciences shares are trading higher after the company announced a year-over-year increase in Q2 EPS results.

Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) reported quarterly losses of $(2.45) per share. This is a 41.67 percent increase over losses of $(4.22) per share from the same period last year.

Senti Biosciences Q2 EPS $(2.45) Up From $(4.22) YoY

Senti Biosciences Announces $8M CIRM Grant To Support Clinical Development Of SENTI-202 CAR-NK Cell Therapy For Hematologic Malignancies; First Tranche Expected In August 2024; Phase 1 Trial Enrolling Patients In US And Australia, Initial Efficacy Data Anticipated By Year-End 2024

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Stock Split

Senti Bio Announces 1-for-10 Reverse Stock Split, Effective Jun. 17

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 109.5% to $2.64 during Thursday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock moved upwards by 37.23% to $1.29. The company's market cap stands at $24.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares moved upwards by 21.37% to $1.59. The company's market cap stands at $1.5 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 13.63% to $2.5. The market value of their outstanding shares is at $1.4 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) stock increased by 13.46% to $3.37. The company's market cap stands at $381.0 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 12.32% to $0.41. The market value of their outstanding shares is at $10.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock declined by 15.5% to $1.01 during Thursday's pre-market session. The market value of their outstanding shares is at $25.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 11.11% to $0.35. The market value of their outstanding shares is at $15.8 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares decreased by 9.1% to $2.5. The market value of their outstanding shares is at $101.3 million. </li>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 8.82% to $16.86. The company's market cap stands at $23.7 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) shares decreased by 8.32% to $3.42. The market value of their outstanding shares is at $120.1 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock decreased by 7.77% to $0.95. The market value of their outstanding shares is at $11.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

AMIX

CNSP

DHAI

Euda Health Holdings Limited - Ordinary Shares

EUDA

GANX

MEDS

SLRX

TRAW

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Senti Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares are trading higher by 102.6% to $0.56 during Monday&#8217;s session after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the <a href="https://www.benzinga.com/pressreleases/24/07/g39572942/senti-bio-awarded-california-institute-for-regenerative-medicines-cirm-grant-for-clinical-developm">ongoing development of SENTI-202</a>.
The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.
Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM&#8217;s support, highlighting SENTI-202&#8217;s potential to improve AML treatment. The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.
Read Also: <a href="https://www.benzinga.com/news/24/07/39575189/whats-going-on-with-gamestop-stock-monday">What&#8217;s Going On With GameStop Stock Monday?</a>
<h2 class="wp-block-heading">Is SNTI A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/SNTI">Senti Biosciences</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of Global Net Lease by the Jul. 11, 2024. Once done, you can expect to receive a nominal payout of $0.28 on Jul. 16, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/SNTI">Senti Biosciences</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.

Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?

Senti Bio shares are trading higher after the company was awarded $8 million from the California Institute for Regenerative Medicines, which will support the ongoing development of SENTI-202.

Senti Bio Awarded $8M Front From The California Institute For Regenerative Medicines, Which Will Support Ongoing Development Of SENTI-202

Senti Biosciences Granted US Patent #12005081 For "Chimeric Receptors And Methods Of Use For Acute Myeloid Leukemia Cancer Antigen Targets" Today

<h3>Gainers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock rose 17.0% to $0.17 during Friday's after-market session. The company's market cap stands at $5.0 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock increased by 12.79% to $3.35. The company's market cap stands at $1.9 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 9.17% to $0.45. The company's market cap stands at $2.1 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock rose 8.77% to $1.24. The market value of their outstanding shares is at $3.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock increased by 6.36% to $1.17. The market value of their outstanding shares is at $7.7 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares rose 5.64% to $0.28. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 7.8% to $0.54 during Friday's after-market session. The company's market cap stands at $2.7 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 7.68% to $0.52. The company's market cap stands at $9.7 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 6.41% to $0.78. The company's market cap stands at $128.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 5.95% to $5.38. The market value of their outstanding shares is at $215.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 5.92% to $0.26. The company's market cap stands at $12.0 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares decreased by 5.01% to $0.95. The market value of their outstanding shares is at $96.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

AZTR

CPHI

RNAZ

RZLT

SBFM

SCNI

TCON

TLSA

TVGN

12 Health Care Stocks Moving In Friday's After-Market Session

Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) reported quarterly losses of $(0.26) per share. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.

Senti Biosciences Q1 EPS $(0.26) Up From $(0.42) YoY

Senti Bio Announces Publication of SENTI-202 Preclinical Data; Says Data Supports The Design Of Phase 1 Clinical Trial With Patient Dosing Anticipated In Q2

Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.28) by 50 percent.

Earnings Misses

Senti Biosciences Q4 2023 GAAP EPS $(0.42) Misses $(0.28) Estimate

<h3>Gainers</h3>
<ul>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 11.1% to $0.99 during Tuesday's after-market session. The market value of their outstanding shares is at $19.4 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 8.14% to $0.2. The company's market cap stands at $9.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 7.29% to $1.47. The company's market cap stands at $4.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares increased by 4.99% to $0.48. The company's market cap stands at $16.0 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares moved upwards by 4.83% to $1.3. The company's market cap stands at $71.5 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares moved upwards by 4.65% to $0.45. The company's market cap stands at $21.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock decreased by 5.1% to $0.29 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 4.82% to $2.77. The company's market cap stands at $286.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 4.81% to $0.42. The company's market cap stands at $18.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock decreased by 4.53% to $0.21. The company's market cap stands at $32.6 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock decreased by 4.26% to $4.5. The company's market cap stands at $21.9 million. </li>
<li>Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) stock fell 3.91% to $14.26. The company's market cap stands at $555.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

CNTB

ENSC

HLTH

HUMA

Intelligent Bio Solutions Inc. - Common Stock

INBS

MBRX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

RDHL

SILK

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 19.8% to $0.75. The market value of their outstanding shares is at $4.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 17.61% to $0.37. The company's market cap stands at $11.1 million. </li>
<li>scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) stock increased by 16.47% to $6.22. The company's market cap stands at $223.0 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares increased by 16.32% to $0.29. The company's market cap stands at $2.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares rose 15.95% to $5.67. The company's market cap stands at $34.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 20.9% to $1.5 during Monday's pre-market session. The company's market cap stands at $3.7 million. </li>
<li>XBiotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIT#NASDAQ">XBIT</a>) shares fell 20.44% to $3.7. The company's market cap stands at $112.6 million. </li>
<li>NexImmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXI#NASDAQ">NEXI</a>) shares declined by 17.86% to $5.75. The market value of their outstanding shares is at $6.0 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 13.3% to $0.91. The company's market cap stands at $7.4 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 11.17% to $0.37. The market value of their outstanding shares is at $16.5 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares decreased by 9.7% to $0.27. The company's market cap stands at $57.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRG

BNOX

CELU

LIFW

NEXI

OPGN

SCPH

SXTP

TBIO

XBIT

12 Health Care Stocks Moving In Monday's Pre-Market Session

Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) (&ldquo;Senti Bio&rdquo; or the &ldquo;Company&rdquo;), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia (&ldquo;AML&rdquo;). The Investigational New Drug (&ldquo;IND&rdquo;) application for SENTI-202 was cleared by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) in December 2023 and the Company anticipates dosing the first patient in the second quarter of 2024. Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (&ldquo;GPC3&rdquo;)-expressing hepatocellular carcinoma (&ldquo;HCC&rdquo;) in China through its partnership with Celest Therapeutics. The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
&ldquo;We have made significant progress toward our mission to advance our Gene Circuit enhanced oncology cell therapies and recently achieved our milestone of IND clearance for SENTI-202, in line with our previous guidance. Despite this progress, we are taking the difficult but necessary steps to enhance our focus on demonstrating clinical proof-of-concept for our Gene Circuit technology and potentially bringing SENTI-202 and SENTI-301A to patients,&rdquo; said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. &ldquo;With these resource allocation efforts, our team will remain laser-focused on the clinical progress of SENTI-202 and supporting our partnership with Celest Therapeutics for SENTI-301A in China. We extend our immense gratitude to our dedicated colleagues impacted by this decision and are committed to supporting them throughout this process.&rdquo;

Guidance

Senti Biosciences  Said Reducing Its Workforce By ~37% As Part Of Prioritizing Its Investment In Lead Clinical Program

<h3>Gainers</h3>
<ul>
<li>Karuna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares rose 30.21% to $1.55. The company's market cap stands at $5.6 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares rose 26.97% to $0.56. The company's market cap stands at $24.8 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares increased by 17.9% to $0.87. The company's market cap stands at $78.6 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 14.14% to $0.51. The company's market cap stands at $19.6 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock moved upwards by 13.45% to $0.51. The market value of their outstanding shares is at $51.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AlloVir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVR#NASDAQ">ALVR</a>) shares declined by 67.0% to $0.77 during Monday's pre-market session. The company's market cap stands at $87.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 37.5% to $2.25. The market value of their outstanding shares is at $1.8 million. </li>
<li>Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) shares fell 26.58% to $16.0. The market value of their outstanding shares is at $430.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 19.55% to $0.89. The market value of their outstanding shares is at $5.1 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares fell 13.16% to $6.67. The market value of their outstanding shares is at $314.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares fell 12.39% to $2.83. The market value of their outstanding shares is at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVR

ATRA

BFRI

CDTX

CSTL

CYCC

KRTX

NBTX

TRIB

Senti Biosciences (SNTI) has issued an update. Senti Biosciences, Inc. announced significant leadership changes with Dr. Timothy Lu stepping down a...

Senti Biosciences Announces Executive Leadership Restructuring

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!



Moving stocks this morning are earnings reports, insider buying, offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 78% alongside heavy pre-market trading.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are soaring over 47% with strong early morning trading.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is surging more than 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318411360&amp;type=PDF&amp;symbol=GLYC&amp;cdn=8f7645b9da4ce31c36360d7737c007dc&amp;companyName=GlycoMimetics+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-24">alongside insider buying</a>.</li>



<li>Anew Medical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/leas-stock-quote/">LEAS</a>) shares are gaining over 38% without any clear news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are increasing more than 24% with strong pre-market trading.</li>



<li>Regis (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgs-stock-quote/">RGS</a>) stock is rising over 21% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318412499&amp;type=PDF&amp;symbol=RGS&amp;cdn=4f01bbb678bba4ddafaac79f77ec0544&amp;companyName=Regis+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-25">senior secured credit facility</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are heading close to 20% higher with heavy pre-market trading today.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is jumping more than 17% <a href="https://www.nasdaq.com/press-release/kaival-brands-announces-closing-60-million-public-offering-2024-06-24">after closing a public offering</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are climbing over 13% on <a href="https://www.nasdaq.com/press-release/bioxcel-therapeutics-announces-positive-topline-results-post-marketing-requirement">topline results from a study</a>.</li>



<li>Captivision (NASDAQ:<a href="https://investorplace.com/stock-quotes/capt-stock-quote/">CAPT</a>) stock is up more than 12% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is plummeting over 25% on plans for a <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">reverse stock split</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) shares are diving more than 22% after a massive rally yesterday.</li>



<li>Beyond Air (NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is tumbling over 19% on <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">lackluster Q4 earnings</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are retreating more than 19% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-113-today/">after rallying yesterday</a>.</li>



<li>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) stock is taking an over 16% beating on a <a href="https://www.nasdaq.com/press-release/solaredge-technologies-inc-announces-proposed-private-offering-300-million">$300 million private offering</a>.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are dropping more than 16% on its <a href="https://www.nasdaq.com/press-release/igc-reports-financial-results-fiscal-year-ended-march-31-2024-2024-06-24">latest earnings report</a>.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) stock is falling over 15% on a <a href="https://www.stocktitan.net/news/OGEN/oragenics-inc-announces-proposed-public-688vwqnwez4o.html">proposed public offering</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are decreasing nearly 12% after a <a href="https://www.nasdaq.com/press-release/dermtech-files-voluntary-chapter-11-protection-2024-06-18">recent bankruptcy filing</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is slipping more than 11% with recent weakness.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Faraday Future&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is falling hard on Tuesday after the electric vehicle (EV) company announced <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">plans to regain compliance</a> with Nasdaq Exchange listing rules.



The biggest blow to FFIE stock comes from the EV company&rsquo;s plans for a reverse stock split. Faraday Future intends to enact a reverse stock split to boost the price of its shares above the $1 minimum bid price required to remain on the Nasdaq Exchange.



Faraday Future hasn&rsquo;t nailed down the exact details of the reverse stock split just yet. However, we know the company is aiming for the ratio to range from one-for-two to one-for-40.



It&rsquo;s likely that Faraday Future will aim for a higher ratio with its reverse stock split. The company notes this would &ldquo;provide a margin of safety for the stock price over the longer term.&rdquo;



<h2>What&rsquo;s Next for FFIE Stock?</h2>



Faraday Future still has other matters to attend to before it can regain listing compliance. The company is also late on its Q1 10-Q filing but plans to have it submitted by the end of July.



After this, Faraday Future will still need approval from shareholders for its reverse stock split. It will seek this approval during its upcoming annual shareholder meeting.



FFIE stock is down 26.7% as of Tuesday morning. This comes with more than 21 million shares traded. That&rsquo;s still well below its daily average trading volume of about 134 million shares.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news available on Tuesday! A few examples include what&rsquo;s going on with shares of Senti Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) and Volcon&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock, as well as the biggest pre-market stock movers this morning. All of that info is ready to go at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-senti-biosciences-snti-stock-up-32-today/">Why Is Senti Biosciences (SNTI) Stock Up 32% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">Why Is Volcon (VLCN) Stock Up 60% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-faraday-future-ffie-stock-down-27-today/">Why Is Faraday Future (FFIE) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Faraday Future (FFIE) Stock Down 27% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Senti Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company&rsquo;s shares this morning.



That has more than 8.5 million shares of SNTI stock changing hands as of this writing. This is a massive jump over its daily average trading volume of about 239,000 shares. It also bears mentioning that the company&rsquo;s <a href="https://finance.yahoo.com/quote/SNTI/key-statistics/">float is 29.16 million units</a>.



The heavy trading this morning comes without any clear news from Senti Biosciences. That includes a lack of press releases or filings with regulators. There&rsquo;s also no analyst coverage that would cause the rally.



Instead, traders will keep in mind that SNTI is a penny stock. That comes from its low closing price of 25 cents yesterday and its market capitalization of just $11.53 million.



<h2>How This Affects SNTI Stock</h2>



Being a penny stock means that SNTI is more subject to volatility. This could be due to speculative traders buying the shares. Another possibility is retail and day traders pumping the stock before a dump.



All of this is to say that investing in SNTI stock right now is a risky move. Traders might want to wait until it has cooled down before considering a position.



SNTI stock is up 32.1% as of Tuesday morning.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news ready to go on Tuesday! Among that is what has shares of Volcon&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock up, the biggest pre-market stock movers and more. All of that info is ready at the following links!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">Why Is Volcon (VLCN) Stock Up 60% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>



<li><a href="https://investorplace.com/2024/06/goldman-sachs-is-pounding-the-table-on-affirm-afrm-stock/">Goldman Sachs Is Pounding the Table on Affirm (AFRM) Stock</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-senti-biosciences-snti-stock-up-32-today/">Why Is Senti Biosciences (SNTI) Stock Up 32% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Senti Biosciences (SNTI) Stock Up 32% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Beyond Air&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is dropping on Tuesday after the commercial-stage medical device and biopharmaceutical company announced its latest earnings results.



The bad news for XAIR stock starts with its <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">revenue of $470,000</a>. That&rsquo;s worse than the $710,600 in revenue that Wall Street was expecting. Investors will note that Beyond Air didn&rsquo;t report revenue last year.



On the flip side of that, the company did report adjusted earnings per share of -36 cents. That&rsquo;s better than the -48 cents per share analysts were expecting. It&rsquo;s also a year-over-year improvement from -67 cents per share.



<h2>What&rsquo;s Next for XAIR Stock?</h2>



Here&rsquo;s what Beyond Air chairman and CEO Steve Lisi <a href="https://finance.yahoo.com/news/beyond-air-reports-fiscal-fourth-201500870.html">said about the company&rsquo;s future</a>.




&ldquo;Over the past few months, we implemented a strategy to conserve capital as we continue building momentum around the commercial launch of LungFit PH. This will significantly reduce our quarterly spend going forward. The impacted R&amp;D projects include our VCAP program, which was placed on hold, and our LungFit GO home-based device for NTM and other lung infections, which we are now bringing in-house for design and development, resulting in a modest delay.&rdquo;




XAIR stock is down 22.4% as of Tuesday morning. That comes with 168,000 shares traded, as compared to a daily average of 338,000 shares.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Tuesday! That includes everything happening with shares of Faraday Future&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock, Senti Biosciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) stock and Volcon&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock this morning. All of this news is ready at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-faraday-future-ffie-stock-down-27-today/">Why Is Faraday Future (FFIE) Stock Down 27% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-senti-biosciences-snti-stock-up-32-today/">Why Is Senti Biosciences (SNTI) Stock Up 32% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">Why Is Volcon (VLCN) Stock Up 60% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-beyond-air-xair-stock-down-22-today/">Why Is Beyond Air (XAIR) Stock Down 22% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Beyond Air (XAIR) Stock Down 22% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning as we break down all of the biggest news sending shares higher and lower on Tuesday!



Moving stocks this morning are a bankruptcy filing, earnings reports, new deals and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chicken Soup for the Soul Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/cssep-stock-quote/">CSSEP</a>) stock is rocketing more than 222% after <a href="https://investorplace.com/2024/07/why-is-chicken-soup-for-the-soul-entertainment-csse-stock-down-29-today/">falling yesterday on a bankruptcy filing</a>. </li>



<li>Chicken Soup for the Soul Entertainment, Inc. &ndash; 9.50% Notes due 2025 (NASDAQ:<a href="https://investorplace.com/stock-quotes/cssen-stock-quote/">CSSEN</a>) are soaring close to 82% after yesterday&rsquo;s drop.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) shares are surging over 60% alongside its <a href="https://www.stocktitan.net/news/RDZN/roadzen-reports-record-revenue-growth-in-its-first-fiscal-year-as-a-47jyl3yay9h1.html">first public year-end earnings</a>.</li>



<li>IMAC (NASDAQ:<a href="https://investorplace.com/stock-quotes/back-stock-quote/">BACK</a>) stock is gaining more than 37% without any clear news this morning.</li>



<li>Versus Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/vs-stock-quote/">VS</a>) shares are rising over 31% after <a href="https://www.marketwatch.com/story/versus-systems-shares-climb-on-interim-ceo-appointment-business-review-589cd51b">naming an interim CEO</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) stock is increasing 30% despite a lack of news this morning.</li>



<li>Chicken Soup for the Soul (NASDAQ:<a href="https://investorplace.com/stock-quotes/csse-stock-quote/">CSSE</a>) shares are climbing more than 19% with its bankruptcy filing.</li>



<li>Ocean Power Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/optt-stock-quote/">OPTT</a>) stock is heading over 16% higher alongside heavy pre-market trading.</li>



<li>US Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/useg-stock-quote/">USEG</a>) shares are jumping more than 14% <a href="https://www.nasdaq.com/press-release/us-energy-corp-announces-transformative-acquisition-targeting-helium-production-2024">on a new acquisition deal</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) stock is up over 14% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is plummeting nearly 35% despite a lack of news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are diving almost 15% without any apparent news today.</li>



<li>Applied DNA Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apdn-stock-quote/">APDN</a>) stock is tumbling close to 12% without any news to note.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are taking a more than 11% beating <a href="https://ca.investing.com/news/company-news/senti-biosciences-awarded-8-million-for-cancer-trial-93CH-3480501">after a cancer funding rally yesterday</a>.</li>



<li>Datasea (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtss-stock-quote/">DTSS</a>) stock is sliding close to 11% after <a href="https://www.marketwatch.com/story/datasea-shares-up-20-on-three-sales-agreements-for-china-units-de49a130">rallying yesterday on sales agreements</a>.</li>



<li>Presto Automation (NASDAQ:<a href="https://investorplace.com/stock-quotes/prst-stock-quote/">PRST</a>) shares are falling over 10% despite a lack of news this morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is decreasing more than 10% without any news to report.</li>



<li>Hudson Pacific Properties (NYSE:<a href="https://investorplace.com/stock-quotes/hpp-stock-quote/">HPP</a>) shares are dropping over 10% despite a lack of relevant news today.</li>



<li>Vintage Wine Estates (NASDAQ:<a href="https://investorplace.com/stock-quotes/vwe-stock-quote/">VWE</a>) stock is slipping more than 10% this morning.</li>



<li>Akso Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/">AHG</a>) shares close out our pre-market stock movers down over 10% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Senti Biosciences to effect 1-for-10 reverse stock split for Nasdaq compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) just reported results for the second quarter of 2024.<ul><li>Senti Biosciences reported earnings per share of -$2.45.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snti-stock-earnings-senti-biosciences-for-q2-of-2024/">SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024

Senti Biosciences GAAP EPS of -$2.45

Intel says it lowered stakes in Astera Labs, Joby Aviation, Senti Biosciences

ALAB

APDN

BACK

BTAI

CAPT

CONN

CSSE

CSSEN

CSSEP

DMTK

DTSS

FFIE

GLYC

INTC

IPDN

JOBY

KAVL

KRKR

LEAS

MLGO

NCPL

NUKK

OPTT

PRST

RDZN

SEDG

USEG

VLCN

VSME

XAIR

ZAPP

Legal

Press Releases

Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Financing

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

Senti Bio Announces Reverse Stock Split

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Comments

Senti Biosciences

Senti Biosciences (SNTI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga